Practical treatment using mitotane for adrenocortical carcinoma

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 21, Issue 3, 2014, Pages 159-165

  Terzolo, Massimo ^a   Zaggia, Barbara ^a   Allasino, Barbara ^a   De Francia, Silvia ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

adjunctive treatment; adrenocortical carcinoma; mitotane; overall survival; recurrence free survival

Indexed keywords

CYTOCHROME P450 3A4; DRUG METABOLIZING ENZYME; MITOTANE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADRENAL CANCER; ADRENAL CORTEX CARCINOMA; ADVANCED CANCER; CANCER PATIENT; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; ENZYME INDUCTION; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HUMAN; MONOTHERAPY; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; REVIEW; STEROID METABOLISM; STEROIDOGENESIS; ADJUVANT CHEMOTHERAPY; ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG INTERACTION; FEMALE; MALE; MORTALITY; NEOPLASM RECURRENCE, LOCAL; PROCEDURES; TREATMENT OUTCOME;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ANTINEOPLASTIC AGENTS, HORMONAL; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MITOTANE; NEOPLASM RECURRENCE, LOCAL; TREATMENT OUTCOME;

EID: 84899968545     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0000000000000056     Document Type: Review

References (30)

1. Fassnacht M, Kroiss M, Allolio B. Update in adrenocortical carcinoma. J Clin Endocrinol Metab 2013; 98:4551-4564.
2. Schteingart DE. Adjuvant mitotane therapy of adrenal cancer: use and controversy. N Engl J Med 2007; 356:2415-2418.
3. Daffara F, De Francia S, Reimondo G, et al. Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly. Endocr Relat Cancer 2008; 15:1043-1053.
4. Schteingart DE. Conventional and novel strategies in the treatment of adrenocortical cancer. Br J Med Biol Res 2000; 33:1197-1200.
5. Asp V, Ulleras E, Lindstrom V, et al. Biphasic hormonal responses to the adrenocorticolytic DDT metabolite 3-methylsulfonyl-DDE in human cells. et al. Toxicol Appl Pharmacol 2010; 242:281-289.
6. Hart MM, Reagan RL, Adamson RH. The effect of isomers of DDD on the ACTH-induced steroid output, histology and ultrastructure of the dog adrenal cortex. Toxicol Appl Pharmacol 1973; 24:127-159.
7. Lin CW, Chang YH, Pu HF. Mitotane exhibits dual effects on steroidogenic enzymes gene transcription under basal and cAMP-stimulating microenvironments in NCI-H295 cells. Toxicol 2012; 298:14-23.
8. Brown RD, Nicholson WE, Chick WT, et al. Effect of o,p'DDD on human adrenal steroid 11b-hydroxylation activity. J Clin Endocrinol Metab 1973; 36:730-733.
9. van Koetsveld PM, Vitale G, Feelders RA, et al. Interferon-β is a potent inhibitor of cell growth and cortisol production in vitro and sensitizes human adrenocortical carcinoma cells to mitotane. Endocr Relat Cancer 2013; 20:443-454.
10. Lehmann TP, Wrzesinski T, Jagodzinski PP. The effect of mitotane on viability, steroidogenesis and gene expression in NCI-H295R adrenocortical cells. Mol Med Rep 2013; 7:893-900.
11. Zsippai A, Szabò DR, Tombol Z, et al. Effects of mitotane on gene expression in the adrenocortical cell line NCI-H295R: a microarray study. Pharmacogenom 2012; 13:1351-1361.
12. Chortis V, Taylor AE, Schneider P, et al. Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5a-reductase, explaining the need for personalized glucocorticoid and androgen replacement. J Clin Endocrinol Metab 2013; 98:161-171.
13. Ghataore L, Chakraborti I, Aylwin SJ, et al. Effects of mitotane treatment on human steroid metabolism: implications for patient management. Endocr Connect 2012; 1:37-47.
14. Poli G, Guasti D, Rapizzi E, et al. Morphofunctional effects of mitotane on mitochondria in human adrenocortical cancer cells. Endocr Relat Cancer 2013; 20:537-550.
15. Hescot S, Slama A, Lombès A, et al. Mitotane alters mitochondrial respiratory chain activity by inducing cytochrome c oxidase defect in human adrenocortical cells. Endocr Relat Cancer 2013; 20:371-381.
16. Terzolo M, Angeli A, Fassnacht M, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 2007; 356:2372-2380.
17. Huang H, Fojo T. Adjuvant mitotane for adrenocortical cancer: a recurring controversy. J Clin Endocrinol Metab 2008; 93:3730-3732.
18. Else T, Williams AR, Sabolch A, et al. Adjuvant therapies, patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma. J Clin Endocrinol Metab 2014; 99:455-461.
19. Habra MA, Ejaz S, Feng L, et al. A retrospective cohort analysis of the efficacy of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma. J Clin Endocrinol Metab 2013; 98:192-197.
20. Fassnacht M, Johanssen S, Fenske W, et al. Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers. J Clin Endocrinol Metab 2010; 95:4925-4932.
21. Terzolo M, Baudin AE, Ardito A, et al. Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection. Eur J Endocrinol 2013; 169:263-270.
22. Hermsen IG, Fassnacht M, Terzolo M, et al. Plasma concentrations of o,p'DDD, o,p'DDA, and o,p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. J Clin Endocrinol Metab 2011; 96:1844-1851.
23. Terzolo M, Berruti A. Adjunctive treatment of adrenocortical carcinoma. Curr Opin Endocrinol Diabetes Obes 2008; 15:221-226.
24. Terzolo M, Ardito A, Zaggia B, et al. Management of adjuvant mitotane therapy following resection of adrenal cancer. Endocrine 2012; 42:521-525.
25. Kerkhofs TM, Baudin E, Terzolo M, et al. Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma. J Clin Endocrinol Metab 2013; 98:4759-4767.
26. D'Avolio A, De Francia S, Basile V, et al. Influence of CYP 2B6 polymorphism on the pharmacokinetics of mitotane. Pharmacogenet Genomics 2013; 23:293-300.
27. Mauclère-Denost S, Leboulleux S, Borget I, et al. High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up. Eur J Endocrinol 2012; 166:261-268.
28. Fassnacht M, Terzolo M, Allolio B, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 2012; 366:2189-2197.
29. Kroiss M, Quinkler M, Johanssen S, et al. Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial. J Clin Endocrinol Metab 2012; 97:3495-3503.
30. Takeshita A, Igarashi-Migitaka J, Koibuchi N, et al. Mitotane induces CYP3A4 expression via activation of the steroid and xenobiotic receptor. J Endocrinol 2013; 216:297-305.